What happened with PRME today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Prime Medicine is developing treatments intended to correct disease-causing DNA changes. Its Prime Editing technology rewrites selected DNA sequences without making a double-stranded break. The company has narrowed its internal focus to editing cells inside the body, chiefly for liver diseases including Wilson disease and alpha-1 antitrypsin deficiency. It remains an early-stage drug developer with no product-sales revenue; selling therapies will require successful development and regulatory approval.
Bristol-Myers Squibb (BMS) is a key paying partner. Through its subsidiary Juno Therapeutics, BMS obtained exclusive worldwide rights to specified Prime Editing technology for T-cell therapies directed at selected targets. Prime Medicine designs the editing reagents, while BMS develops, manufactures and commercializes the therapies using cells edited outside the body. Prime Medicine has received an upfront license payment and can earn further payments when programs reach agreed milestones, plus royalties if products sell. Its operations have also relied on stock offerings, and continued development requires additional funding.
The business depends on licensed intellectual property with limits on its use. Broad Institute licenses exclude human germline modification and require development progress and payments; Broad can reclaim rights to certain gene targets under specified conditions. A separate dispute with Beam concerns whether Prime Medicine has the contractual right to pursue its alpha-1 antitrypsin deficiency program. An adverse outcome could require it to stop work on that program and transfer it to Beam.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Prime Medicine's outlook hinges on clinical success in liver-directed editing and continued access to foundational Prime Editing patents licensed from Broad Institute, which is not on this list.
Beam Therapeutics competes with Prime Medicine in alpha-1 antitrypsin deficiency (AATD), but also licenses Prime Editing rights that could bring Prime milestone payments and royalties, while licensing enabling technology back to Prime. Watch Beam's AATD treatment results for competitive pressure; payments to Prime depend on progress and sales of products covered by their agreement.
Intellia Therapeutics and Prime Medicine both need to show that editing DNA inside patients can be safe and lasting, with Prime focused on the liver. Intellia's Phase 3 lonvo-z program for hereditary angioedema and nex-z program for transthyretin amyloidosis offer concrete safety and durability results to watch.
Bristol Myers Squibb pays Prime Medicine to use its editing technology and Prime-designed reagents in T cells edited outside the body for therapeutic use. Prime has received upfront funding; progress in these partnered T-cell therapies could unlock further milestone payments and, if sold, royalties.
CRISPR Therapeutics develops medicines that edit cells inside the body and engineered T-cell treatments, paralleling Prime Medicine's internal pipeline and partnered T-cell work. Its CAR T candidates for autoimmune disease and cancer are worth watching for clinical validation of edited T-cell medicines.
Editas Medicine and Prime Medicine both develop medicines that edit DNA inside the body, including in liver cells, so editing safety and delivery advances matter to both. Watch Editas's cardiovascular candidate EDIT-401 and its liver-cell work for progress in getting editing medicines to their intended cells.
Wave Life Sciences offers a competing route to treating AATD by editing RNA, while Prime Medicine aims to correct DNA for the same disease. Wave's Phase 1/2 RNA-editing study is the concrete clinical comparison to watch.
Ultragenyx Pharmaceutical's UX701 gene therapy competes with Prime Medicine's gene-editing approach to treating Wilson disease.
Arrowhead's RNA-based AATD treatments compete with Prime Medicine's effort to correct the disease's genetic cause. Arrowhead reduces production of selected proteins by silencing their RNA messages rather than correcting DNA; its AATD results are the relevant comparison for Prime.
Metagenomi Therapeutics and Prime Medicine both depend on effective editing inside the body: Metagenomi inserts genes or switches them off, while Prime corrects DNA precisely. Watch whether Metagenomi's MGX-001 hemophilia A program can deliver lasting protein replacement through gene insertion.
Precision BioSciences and Prime Medicine both depend on safely delivering editors into the body, although Precision uses ARCUS and Prime uses Prime Editing. Precision's PBGENE-HBV and PBGENE-DMD programs are concrete places to watch for clinical evidence on delivery and editing safety.
Vertex Pharmaceuticals' cystic fibrosis treatments compete for patients with Prime Medicine's early-stage work on permanent correction of cystic-fibrosis-related lung disease. Progress in Vertex's cystic fibrosis therapies is the relevant news for Prime's program, rather than Vertex's broader medicine sales.
Scribe Therapeutics and Prime Medicine both need genetic medicines delivered inside the body to produce safe, lasting effects, with Scribe targeting cardiovascular and metabolic disease and Prime focusing on liver-directed editing. Watch delivery and durability evidence from Scribe's programs targeting LDL cholesterol, Lp(a) and triglycerides.
Bristol-Myers Squibb Co. earningsBMY
Bristol Myers Squibb’s report may show how its partnered ex vivo T-cell therapies are progressing, a path that could bring Prime Medicine milestone payments.
Look for updates on the partnered programs and evidence that they are advancing toward milestones. Clear progress would bring Prime closer to potential milestone payments; limited progress or no update would not change the upfront funding Prime has received, but would leave less evidence for further collaboration income.
Vertex Pharmaceuticals Inc earningsVRTX
Vertex’s report will show how its cystic-fibrosis treatments are progressing, a source of competition for Prime Medicine’s early-stage lung-disease program.
Focus on progress in Vertex’s cystic-fibrosis treatments, not changes in its overall medicine sales. Continued progress would raise the bar for Prime to attract patients and establish the value of a future treatment; setbacks could ease that competitive pressure, but would not show that Prime’s gene-correction approach works.
Beam Therapeutics Inc. earningsBEAM
Beam’s report may show progress in its AATD program, a competing effort to Prime Medicine’s and a separate part of the companies’ licensing relationship.
Watch for clinical progress in Beam’s AATD treatment, and keep competition separate from licensing income. Clear progress would raise the bar for Prime’s own AATD program; limited progress could mean less competitive pressure, but would not prove Prime’s treatment works. Milestone payments and royalties depend on covered products meeting contractual progress or sales conditions, so Beam’s progress alone does not establish that Prime will be paid.
Ultragenyx Pharmaceutical Inc. earningsRARE
Ultragenyx’s report may show progress in UX701, its Wilson disease gene therapy and a direct competitor to Prime Medicine’s liver-directed editing program.
Focus on clinical progress in UX701, not Ultragenyx’s overall results. Clear progress would strengthen competition for Prime’s Wilson disease program and raise expectations for treatment; slow progress or setbacks would ease that pressure, but would not show that Prime’s approach works or can advance clinically.
Intellia Therapeutics, Inc earningsNTLA
Intellia’s report may provide safety and durability evidence from editing inside patients, showing which shared delivery challenges matter to Prime Medicine’s in vivo programs.
Look at safety and whether effects last in Intellia’s hereditary angioedema and transthyretin amyloidosis programs. Strong results would reduce uncertainty about in vivo editing in general, but Intellia uses a different technology and cannot validate Prime Editing; safety problems or weak durability would show that delivery and lasting-effect risks remain relevant to Prime.
Prime Medicine, Inc. earningsThis company
Prime Medicine has no product-sale revenue, so its report will show how quickly it is spending to advance research and whether its funding is keeping pace.
Read cash used in operations alongside cash and investments at quarter-end, then check for new funding and progress on the company’s priority programs. Slower cash use or new funding with continued progress would support the plan to fund operations into 2027; faster cash use without new funding, or stalled programs, would make that runway less secure and leave more of the research dependent on financing.
